<DOC>
	<DOCNO>NCT02108743</DOCNO>
	<brief_summary>The purpose study determine dynamic hyperinflation see patient idiopathic pulmonary artery hypertension ( iPAH ) improve albuterol therapy .</brief_summary>
	<brief_title>Albuterol Dynamic Hyperinflation Idiopathic Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Only small study evaluate relationship iPAH , expiratory flow limitation , exercise dyspnea . While patient iPAH demonstrate airway involvement , demonstrate dynamic hyperinflation ( DH ) , define variable temporary increase end-expiratory lung volume , report increase dyspnea exertion maximal testing . There continued need adjuvant therapy iPAH , bronchodilator potential ameliorate dyspnea exercise , could lead improve quality life disable condition . This study investigate presence airway involvement population measure dynamic hyperinflation , improvement function use inhale albuterol .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>18 year age great . Idiopathic Pulmonary Arterial Hypertension , Familial Pulmonary Arterial Hypertension . Forced expiratory flow 75 % ( FEF75 % ) ≤ 65 % predict . Clinical instability change medication therapy precede 3 month . Allergy intolerance inhale albuterol . Body mass index &gt; 30 Active tobacco use , &gt; 10 packyear smoke history . Lung disease pulmonary hypertension Forced expiratory volume 1 second ( FEV1 ) ≤ 80 % predict . Pregnancy Inability perform pulmonary function test . Inability perform cardiopulmonary exercise testing . Supplemental oxygen requirement . Inability read understand English . Historical 6minute walk distance &lt; 150 meter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>